Tag: cancer

CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today announced that the Company’s stockholders have approved a proposal to effect a reverse split, which was voted on at the Company’s 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 2025, and that its Board of Directors (the “Board of Directors” or “Board”) approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 13, 2025.

Le nouveau centre favorisera le développement d’une main-d’œuvre hautement qualifiée et compétente dans le domaine nucléaire

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men¹—and encourages them to take control of their health.

mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments.